| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Outcomes in chronic myeloid leukemia (CML) have vastly improved after
introducing tyrosine kinase inhibitors. However, patients in low and
middle-income countries (LMICs) face many challenges due to social and
1. Demographic and social data .
|Table 2. Knowledge about disease and treatment.|
|Table 3. Drug taking practices.|
|Table 4. Financial impact of treatment.
|Figure 1. Treatment related adverse effects (alone or in combination).